ATE243530T1 - Virus impfstoff - Google Patents
Virus impfstoffInfo
- Publication number
- ATE243530T1 ATE243530T1 AT96913234T AT96913234T ATE243530T1 AT E243530 T1 ATE243530 T1 AT E243530T1 AT 96913234 T AT96913234 T AT 96913234T AT 96913234 T AT96913234 T AT 96913234T AT E243530 T1 ATE243530 T1 AT E243530T1
- Authority
- AT
- Austria
- Prior art keywords
- virus
- strains
- inactivated
- neuraminidase
- hemagglutinin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/25—Varicella-zoster virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/430,971 US5976552A (en) | 1995-04-28 | 1995-04-28 | Virus vaccines |
PCT/US1996/005904 WO1996033738A1 (en) | 1995-04-28 | 1996-04-26 | Improved virus vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE243530T1 true ATE243530T1 (de) | 2003-07-15 |
Family
ID=23709884
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT96913234T ATE243530T1 (de) | 1995-04-28 | 1996-04-26 | Virus impfstoff |
Country Status (12)
Country | Link |
---|---|
US (2) | US5976552A (de) |
EP (1) | EP0830141B1 (de) |
CN (1) | CN1141977C (de) |
AT (1) | ATE243530T1 (de) |
AU (1) | AU696690B2 (de) |
CA (1) | CA2222283C (de) |
DE (1) | DE69628834T2 (de) |
DK (1) | DK0830141T3 (de) |
ES (1) | ES2201184T3 (de) |
HK (1) | HK1013595A1 (de) |
PT (1) | PT830141E (de) |
WO (1) | WO1996033738A1 (de) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6485729B1 (en) * | 1993-09-13 | 2002-11-26 | Protein Sciences Corporation | Neuraminidase-supplemented compositions |
ATE329497T1 (de) * | 1996-10-31 | 2006-07-15 | Slk Foundation | Aromatische zusammensetzung, herstellung und verwendung derselben |
WO1998046262A1 (en) * | 1997-04-16 | 1998-10-22 | Connaught Laboratories, Inc. | Anti-influenza compositions supplemented with neuraminidase |
ATE422364T1 (de) * | 1998-12-17 | 2009-02-15 | Sanofi Pasteur Ltd | Multivalente immunogenische zusammensetzung, die eine rsv untereinheit zusammensetzung und ein influenzavirus präparat enthält |
AT407958B (de) * | 1999-02-11 | 2001-07-25 | Immuno Ag | Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation |
BR0014281A (pt) * | 1999-09-24 | 2002-05-21 | Smithkline Beecham Biolog | Vacina contra vìrus de gripe intranasal |
US7122018B2 (en) | 2000-12-26 | 2006-10-17 | Sensormedics Corporation | Device and method for treatment of wounds with nitric oxide |
CA2498319A1 (en) * | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
WO2004035086A2 (en) | 2002-10-16 | 2004-04-29 | Hunter Samuel F | Method for treatment of demyelinating central nervous system disease using gm-csf |
US20060110740A1 (en) * | 2003-01-20 | 2006-05-25 | Julia Hurwitz | Use of sendai virus as a human parainfluenza vaccine |
US7282353B2 (en) * | 2003-08-19 | 2007-10-16 | Academia Sinica | Protein isolation |
JP2008527009A (ja) | 2005-01-19 | 2008-07-24 | バクシネート コーポレーション | 病原体関連分子パターンおよび抗原を含む組成物ならびに免疫応答を刺激するためのそれらの使用 |
GB0504436D0 (en) * | 2005-03-03 | 2005-04-06 | Glaxosmithkline Biolog Sa | Vaccine |
US11865172B2 (en) | 2005-04-21 | 2024-01-09 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
EP1899470A4 (de) * | 2005-05-23 | 2009-07-29 | Vaxin Inc | System zur schnellen herstellung replikationskompetenter adenovirus-freier rekombinanter adenovirusvektoren mit hohem titer |
US20070116785A1 (en) * | 2005-11-18 | 2007-05-24 | Miller Christopher C | Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant |
TWI477602B (zh) | 2006-02-09 | 2015-03-21 | Educational Foundation Jichi Medical Univ | Novel viral vector |
US9333249B2 (en) | 2006-02-09 | 2016-05-10 | Educational Foundation Jichi Medical University | Recombinant baculovirus vaccine |
AU2007224034B2 (en) | 2006-03-07 | 2012-03-29 | Vaxinnate Corporation | Compositions that include hemagglutinin, methods of making and methods of use thereof |
CA2680600A1 (en) * | 2007-03-12 | 2008-09-18 | Antigen Express, Inc. | Li-rnai involved li suppression in cancer immunotherapy |
CN101307310B (zh) * | 2007-05-15 | 2012-08-08 | 康泰生医科技股份有限公司 | 具有提高产率及免疫原性的重组蛋白质表达系统 |
EP2014279A1 (de) * | 2007-06-22 | 2009-01-14 | Pevion Biotech AG | Virosomen enthaltend Haemagglutinin, das von über Zelllinien hergestellten Influenza-Viren stammt, Zusammensetzungen, Herstellungsverfahren, Verwendung davon |
WO2009128949A2 (en) * | 2008-04-18 | 2009-10-22 | Vaxinnate Corporation | Compositions of dengue viral proteins and methods of use |
WO2010144797A2 (en) | 2009-06-12 | 2010-12-16 | Vaccine Technologies, Incorporated | Influenza vaccines with enhanced immunogenicity and uses thereof |
AU2011203740B2 (en) * | 2010-01-06 | 2014-11-13 | Vaxinnate Corporation | Methods and compositions for providing protective immunity in the elderly |
EP2579892A2 (de) | 2010-06-09 | 2013-04-17 | Vaccine Technologies, Incorporated | Therapeutische immunisierung von hiv-infizierten personen mit stabiler antiretroviraler behandlung |
WO2012060678A2 (es) * | 2010-11-02 | 2012-05-10 | Zepeda Lopez Hector Manuel | Vacunas novedosas contra el virus de la influencia pandémica a/h1n1 |
WO2012129295A1 (en) | 2011-03-21 | 2012-09-27 | Vaxin Inc. | Rapid and prolonged immunologic-therapeutic |
US8932598B2 (en) | 2012-08-28 | 2015-01-13 | Vaxinnate Corporation | Fusion proteins and methods of use |
BR112018014109A2 (pt) | 2016-01-11 | 2018-12-11 | Verndari Inc | composições de microagulhas e métodos de uso das mesmas |
CN105854009A (zh) * | 2016-05-03 | 2016-08-17 | 重庆三杰众鑫生物工程有限公司 | 应用番鸭肝炎病毒制备灭活疫苗的制备方法 |
MX2019014943A (es) | 2018-12-12 | 2020-08-06 | Cambridge Tech Llc | Vacuna universal contra la gripe. |
WO2023081798A1 (en) | 2021-11-05 | 2023-05-11 | Sanofi Pasteur Inc. | Multivalent influenza vaccines comprising recombinant hemagglutinin and neuraminidase and methods of using the same |
WO2023079113A1 (en) | 2021-11-05 | 2023-05-11 | Sanofi | Hybrid multivalent influenza vaccines comprising hemagglutinin and neuraminidase and methods of using the same |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2667245B1 (fr) * | 1990-10-01 | 1992-11-06 | Rhone Merieux | Association vaccinale contre les pathogenes infectieux. |
WO1994001133A1 (en) * | 1992-07-08 | 1994-01-20 | Schering Corporation | Use of gm-csf as a vaccine adjuvant |
-
1995
- 1995-04-28 US US08/430,971 patent/US5976552A/en not_active Expired - Lifetime
-
1996
- 1996-04-26 DK DK96913234T patent/DK0830141T3/da active
- 1996-04-26 PT PT96913234T patent/PT830141E/pt unknown
- 1996-04-26 AT AT96913234T patent/ATE243530T1/de active
- 1996-04-26 ES ES96913234T patent/ES2201184T3/es not_active Expired - Lifetime
- 1996-04-26 WO PCT/US1996/005904 patent/WO1996033738A1/en active IP Right Grant
- 1996-04-26 DE DE69628834T patent/DE69628834T2/de not_active Expired - Lifetime
- 1996-04-26 CN CNB961950706A patent/CN1141977C/zh not_active Expired - Fee Related
- 1996-04-26 CA CA2222283A patent/CA2222283C/en not_active Expired - Fee Related
- 1996-04-26 AU AU56312/96A patent/AU696690B2/en not_active Revoked
- 1996-04-26 EP EP96913234A patent/EP0830141B1/de not_active Expired - Lifetime
-
1998
- 1998-12-22 HK HK98114898A patent/HK1013595A1/xx not_active IP Right Cessation
-
1999
- 1999-01-22 US US09/235,901 patent/US20020071848A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN1189103A (zh) | 1998-07-29 |
HK1013595A1 (en) | 1999-09-03 |
CA2222283A1 (en) | 1996-10-31 |
DE69628834D1 (de) | 2003-07-31 |
CN1141977C (zh) | 2004-03-17 |
DE69628834T2 (de) | 2004-05-06 |
DK0830141T3 (da) | 2003-10-20 |
ES2201184T3 (es) | 2004-03-16 |
EP0830141A1 (de) | 1998-03-25 |
US20020071848A1 (en) | 2002-06-13 |
AU696690B2 (en) | 1998-09-17 |
AU5631296A (en) | 1996-11-18 |
PT830141E (pt) | 2003-11-28 |
CA2222283C (en) | 2015-02-03 |
EP0830141B1 (de) | 2003-06-25 |
WO1996033738A1 (en) | 1996-10-31 |
US5976552A (en) | 1999-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE243530T1 (de) | Virus impfstoff | |
Hashigucci et al. | Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin | |
EP0705109B2 (de) | Adjuvantien für impfstoffe gegen das respiratorische synzitialvirus | |
AU2684792A (en) | Porcine reproductive respiratory syndrome vaccine and diagnostic | |
FI102616B1 (fi) | Menetelmä rokotteen valmistamiseksi ihmisen parainfluenssa-viruksen tyyppiä 3 varten ja menetelmässä käytettävä ilmentämisjärjestelmä | |
Kodihalli et al. | A type-specific avian influenza virus subunit vaccine for turkeys: induction of protective immunity to challenge infection | |
DK0584348T3 (da) | Genetisk vaccine mod immundefektvirusser | |
KR920703103A (ko) | 인터루킨을 함유하는 안정한 백신 조성물 | |
MX9802285A (es) | Vacunas y glicoproteinas de virus de parainfluenza. | |
ATE101200T1 (de) | Impfstoffe gegen menschliche respiratorische viren. | |
Downie | Neuraminidase-and hemagglutinin-inhibiting antibodies in serum and nasal secretions of volunteers immunized with attenuated and inactivated influenza B/Eng/13/65 virus vaccines | |
AU3887695A (en) | Interleukin-12 as an adjuvant for paramyxoviridae vaccines | |
GB1229888A (de) | ||
FI95871B (fi) | Menetelmä HIV-hiukkasimmunogeenin ja sen vasta-aineen valmistamiseksi | |
DE69720024D1 (de) | Immunisierungsverfahren in zwei schritten gegen pyramyxoviridae-viren unter verwendung abgeschwächter viraler stämme und preparation von proteinuntereinheiten | |
Liashenko et al. | Measles IgA in the nasal washings of adult volunteers and children immunized intranasally with measles vaccine L-16 | |
PT100460A (pt) | Partiiculas derivadas de virus de herpes e vacinas que as contem | |
Trudel et al. | Efficient intranasal vaccination of mice against human respiratory syncytial virus with an experimental iscoms subunit vaccine | |
Reddy et al. | Efficacy of a combined live attenuated canine distemper and inactivated rabies vaccine in dogs | |
Fatunmbi | Development and improvement of avian influenza vaccines in turkeys. | |
Smith et al. | In vitro studies on suppression of the immune response to influenza virus surface proteins | |
IE45441L (en) | Influenza virus vaccine. | |
CO5040217A1 (es) | Vacunas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0830141 Country of ref document: EP |